Cargando…

Defining COVID-19–associated pulmonary aspergillosis: systematic review and meta-analysis

BACKGROUND: Pulmonary aspergillosis may complicate coronavirus disease 2019 (COVID-19) and contribute to excess mortality in intensive care unit (ICU) patients. The disease is poorly understood, in part due to discordant definitions across studies. OBJECTIVES: We sought to review the prevalence, dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Kariyawasam, Ruwandi M., Dingle, Tanis C., Kula, Brittany E., Vandermeer, Ben, Sligl, Wendy I., Schwartz, Ilan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828380/
https://www.ncbi.nlm.nih.gov/pubmed/35150878
http://dx.doi.org/10.1016/j.cmi.2022.01.027
_version_ 1784647832102240256
author Kariyawasam, Ruwandi M.
Dingle, Tanis C.
Kula, Brittany E.
Vandermeer, Ben
Sligl, Wendy I.
Schwartz, Ilan S.
author_facet Kariyawasam, Ruwandi M.
Dingle, Tanis C.
Kula, Brittany E.
Vandermeer, Ben
Sligl, Wendy I.
Schwartz, Ilan S.
author_sort Kariyawasam, Ruwandi M.
collection PubMed
description BACKGROUND: Pulmonary aspergillosis may complicate coronavirus disease 2019 (COVID-19) and contribute to excess mortality in intensive care unit (ICU) patients. The disease is poorly understood, in part due to discordant definitions across studies. OBJECTIVES: We sought to review the prevalence, diagnosis, treatment, and outcomes of COVID-19–associated pulmonary aspergillosis (CAPA) and compare research definitions. DATA SOURCES: PubMed, Embase, Web of Science, and MedRxiv were searched from inception to October 12, 2021. STUDY ELIGIBILITY CRITERIA: ICU cohort studies and CAPA case series including ≥3 patients were included. PARTICIPANTS: Adult patients in ICUs with COVID-19. INTERVENTIONS: Patients were reclassified according to four research definitions. We assessed risk of bias with an adaptation of the Joanna Briggs Institute cohort checklist tool for systematic reviews. METHODS: We calculated CAPA prevalence using the Freeman-Tukey random effects method. Correlations between definitions were assessed with Spearman's rank test. Associations between antifungals and outcome were assessed with random effects meta-analysis. RESULTS: Fifty-one studies were included. Among 3297 COVID-19 patients in ICU cohort studies, 313 were diagnosed with CAPA (prevalence 10%; 95% CI 8%–13%). Two hundred seventy-seven patients had patient-level data allowing reclassification. Definitions had limited correlation with one another (ρ = 0.268–0.447; p < 0.001), with the exception of Koehler and Verweij (ρ = 0.893; p < 0.001); 33.9% of patients reported to have CAPA did not fulfill any research definitions. Patients were diagnosed after a median of 8 days (interquartile range 5–14) in ICUs. Tracheobronchitis occurred in 3% of patients examined with bronchoscopy. The mortality rate was high (59.2%). Applying CAPA research definitions did not strengthen the association between mould-active antifungals and survival. CONCLUSIONS: The reported prevalence of CAPA is significant but may be exaggerated by nonstandard definitions.
format Online
Article
Text
id pubmed-8828380
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-88283802022-02-10 Defining COVID-19–associated pulmonary aspergillosis: systematic review and meta-analysis Kariyawasam, Ruwandi M. Dingle, Tanis C. Kula, Brittany E. Vandermeer, Ben Sligl, Wendy I. Schwartz, Ilan S. Clin Microbiol Infect Systematic Review BACKGROUND: Pulmonary aspergillosis may complicate coronavirus disease 2019 (COVID-19) and contribute to excess mortality in intensive care unit (ICU) patients. The disease is poorly understood, in part due to discordant definitions across studies. OBJECTIVES: We sought to review the prevalence, diagnosis, treatment, and outcomes of COVID-19–associated pulmonary aspergillosis (CAPA) and compare research definitions. DATA SOURCES: PubMed, Embase, Web of Science, and MedRxiv were searched from inception to October 12, 2021. STUDY ELIGIBILITY CRITERIA: ICU cohort studies and CAPA case series including ≥3 patients were included. PARTICIPANTS: Adult patients in ICUs with COVID-19. INTERVENTIONS: Patients were reclassified according to four research definitions. We assessed risk of bias with an adaptation of the Joanna Briggs Institute cohort checklist tool for systematic reviews. METHODS: We calculated CAPA prevalence using the Freeman-Tukey random effects method. Correlations between definitions were assessed with Spearman's rank test. Associations between antifungals and outcome were assessed with random effects meta-analysis. RESULTS: Fifty-one studies were included. Among 3297 COVID-19 patients in ICU cohort studies, 313 were diagnosed with CAPA (prevalence 10%; 95% CI 8%–13%). Two hundred seventy-seven patients had patient-level data allowing reclassification. Definitions had limited correlation with one another (ρ = 0.268–0.447; p < 0.001), with the exception of Koehler and Verweij (ρ = 0.893; p < 0.001); 33.9% of patients reported to have CAPA did not fulfill any research definitions. Patients were diagnosed after a median of 8 days (interquartile range 5–14) in ICUs. Tracheobronchitis occurred in 3% of patients examined with bronchoscopy. The mortality rate was high (59.2%). Applying CAPA research definitions did not strengthen the association between mould-active antifungals and survival. CONCLUSIONS: The reported prevalence of CAPA is significant but may be exaggerated by nonstandard definitions. The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2022-07 2022-02-10 /pmc/articles/PMC8828380/ /pubmed/35150878 http://dx.doi.org/10.1016/j.cmi.2022.01.027 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Systematic Review
Kariyawasam, Ruwandi M.
Dingle, Tanis C.
Kula, Brittany E.
Vandermeer, Ben
Sligl, Wendy I.
Schwartz, Ilan S.
Defining COVID-19–associated pulmonary aspergillosis: systematic review and meta-analysis
title Defining COVID-19–associated pulmonary aspergillosis: systematic review and meta-analysis
title_full Defining COVID-19–associated pulmonary aspergillosis: systematic review and meta-analysis
title_fullStr Defining COVID-19–associated pulmonary aspergillosis: systematic review and meta-analysis
title_full_unstemmed Defining COVID-19–associated pulmonary aspergillosis: systematic review and meta-analysis
title_short Defining COVID-19–associated pulmonary aspergillosis: systematic review and meta-analysis
title_sort defining covid-19–associated pulmonary aspergillosis: systematic review and meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828380/
https://www.ncbi.nlm.nih.gov/pubmed/35150878
http://dx.doi.org/10.1016/j.cmi.2022.01.027
work_keys_str_mv AT kariyawasamruwandim definingcovid19associatedpulmonaryaspergillosissystematicreviewandmetaanalysis
AT dingletanisc definingcovid19associatedpulmonaryaspergillosissystematicreviewandmetaanalysis
AT kulabrittanye definingcovid19associatedpulmonaryaspergillosissystematicreviewandmetaanalysis
AT vandermeerben definingcovid19associatedpulmonaryaspergillosissystematicreviewandmetaanalysis
AT sliglwendyi definingcovid19associatedpulmonaryaspergillosissystematicreviewandmetaanalysis
AT schwartzilans definingcovid19associatedpulmonaryaspergillosissystematicreviewandmetaanalysis